Question Number: 188
PDR Number: SQ22-000139
Date Submitted: 24/02/2022
Department or Body: Department of Health
145. No data has been reported to the Therapeutic Goods Administration (TGA) regarding lipid nanoparticles clotting red blood cells. The TGA is not aware of any data or published studies in referenced scientific journals that indicate that the lipid nanoparticles contained in the vaccine or the spike protein cause blood clotting.
148. No study was submitted to the TGA investigating the impact of the spike protein in different blood types. This is not a requirement as per the international guidelines for vaccines. There have been hundreds of published studies on the efficacy of COVID-19 vaccines as of March 2022, but none have shown or suggested that the blood type of an individual has an effect on the response of a person to the vaccine or spike protein.
